FAQs and Guidances

Federal government:

NCI source book and resources: clinical and laboratory operations
NCI Emergency Resources: What people with cancer should know about the coronavirus
NCI guidance: Interim guidance for patients on clinical trials supported by the NCI Cancer Therapy Evaluation Program (CTEP) and the NCI Community Oncology Research Program (NCORP).
CTEP coronavirus guidance
COVID-19 scientific interest group
FDA guidance: Conduct of clinical trials of medical products during COVID-19 pandemic
FDA guidance update: Blood donations
- More FDA updates: Medical Countermeasures Initiative, on COVID-19
- FDA continues to facilitate access to crucial medical products, Including ventilators
- FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency
- A message to patients with cancer and Health Care Providers About COVID-19
- Update: Diagnostic testing for COVID-19

Professional societies:

American Society of Clinical Oncology FAQ: Emerging issues and challenges in caring for patients with cancer during the coronavirus pandemic
American Cancer Society FAQ: Common questions about the new coronavirus outbreak
- ACS clinical guidance: COVID-19 elective case triage guidelines for surgical care
- Create a surgical review committee for COVID-19-related surgical triage decision making
- COVID-19 and 2020 ACS Grants
Society for Immunotherapy of Cancer Resources: Patient management and basic and translational research
Community Oncology Alliance resources: Coronavirus (COVID-19) practice resources and protocols
Leukemia & Lymphoma Society FAQ: Resources and what you should know about the coronavirus
American Society for Radiation Oncology FAQ: COVID-19 recommendations and information
American College of Surgeons resources: For the surgical community
Society for Immunotherapy of Cancer resources: Implications for patients, translational research
American Society for Transplantation and Cellular Therapy resources
European Blood and Marrow Transplantation Society recommendations
World Marrow Donor Association resources

Research centers:

St. Jude Children’s Research Hospital FAQ: COVID-19 and children with cancer
Journal of the National Comprehensive Cancer Network: How to manage cancer care during COVID-19 pandemic

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30.

January 28, 2026

Vol.52 No.03

Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.

January 23, 2026

Vol.52 No.03

By Claire Marie Porter

Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several aggressive cuts the White House had proposed for NIH.

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Sometime next week, the Senate is expected to vote on a legislative package that would determine the fiscal year 2026 spending levels for much of the federal government. xxx:moreReaders of The Cancer Letter may be breathing a sigh of relief that NIH seems like

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer.

January 23, 2026

Vol.52 No.03

By E. Anders Kolb

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

Vol.52 No.03

By Tanya Dorff

FAQs and Guidances

YOU MAY BE INTERESTED IN

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Blood Cancer United: A new name at the right moment

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Renew today!

Subscriber content

Never miss an issue!

Login

FAQs and Guidances

YOU MAY BE INTERESTED IN

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Blood Cancer United: A new name at the right moment

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Never miss an issue!

Login

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched